Long noncoding RNAs: a potential novel class of cancer biomarkers

Yarmishyn, Aliaksandr A.; Kurochkin, Igor V.

doi:10.3389/fgene.2015.00145

Cited by 231 publications

(183 citation statements)

References 115 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…Accumulating evidence revealed disruptive expression of lncRNAs in various types of human cancers, and these lncRNAs are capable of regulating diverse cellular processes such as tumor cell growth, cell apoptosis, cell invasion and metastasis, and tumor cells sensitivity to chemotherapy drugs 24, 25. Moreover, a growing number of studies have demonstrated that dysregulated lncRNAs have been identified as critical regulators during the tumorigenesis and cancer progression, and some of these lncRNAs are determined as significant factors for clinical implication.…”

Section: Discussionmentioning

confidence: 99%

Identification of differential expressed lncRNAs in human thyroid cancer by a genome‐wide analyses

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Recently, a growing number of evidence has revealed that long noncoding RNAs (lncRNAs) act as key regulators in various cellular biologic processes, and dysregulation of lncRNAs involves in tumorigenesis and cancer progression. However, the expression pattern, clinical relevance, and biologic function of most lncRNAs in human thyroid cancer remain unclear. To identify more thyroid‐cancer‐associated lncRNAs, we analyzed the expression profile of lncRNAs in thyroid cancer tissues and adjacent normal or non‐tumor tissues using RNA sequencing data and gene microarray data from The Cancer Genome Atlas and Gene Expression Omnibus. Annotation and analyses of these data revealed that hundreds of lncRNAs are differentially expressed in thyroid cancer tissues when compared with normal tissues. By copy number variation analyses, we identified that some of those dysregulated lncRNAs genome locus are accompanied with the copy number amplification or deletion. Moreover, some lncRNAs expression levels are significantly associated with thyroid cancer patients overall or recurrence‐free survival time, such as RUNDC3A‐AS1, FOXD2‐AS1, PAX8‐AS1, and CRYM‐AS1. Furthermore, we validated an lncRNA termed LINC00704 in thyroid cancer cells by performing loss of function assays. Downregulation of LINC00704 could significantly impair thyroid cancer cells proliferation, colony formation, inhibit cell‐cycle progression and cell invasion, and induce cell apoptosis. Taken together, our findings reveal that lots of lncRNAs are dysregulated and may play critical roles in thyroid cancer, and this study could provide useful resource for identification and investigation of novel lncRNA candidates for thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of differential expressed lncRNAs in human thyroid cancer by a genome‐wide analyses

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…18 Their expression profiling in various cancer types have been widely examined, and many of these lncRNAs were correlated with cancer diagnosis and prognosis. 19 A study was performed with a total of 1240 patients from 15 articles that were included, and the results indicated that a significantly shorter over survival time was observed in patients with high expression level of UCA1 in various cancers. 20 Overexpression of lncRNA UCA1 promoted osteosarcoma progression and correlates with poor prognosis.…”

mentioning

confidence: 99%

LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495

et al. 2017

View full text Add to dashboard Cite

Long non-coding RNAs have recently emerged as important regulators in the pathogenesis and progression of cancers. The long non-coding RNA urothelial carcinoma-associated 1 is reportedly upregulated and functions as an oncogene in some tumors. However, the role of urothelial carcinoma-associated 1 in renal cell carcinoma is not well elucidated so far. In this study, we found that urothelial carcinoma-associated 1 was overexpressed in renal cell carcinoma tissues compared with the adjacent normal tissues, and higher urothelial carcinoma-associated 1 expression levels were positively associated with advanced tumor stage and poor survival time in renal cell carcinoma patients. Further studies showed that knockdown of urothelial carcinoma-associated 1 suppressed renal cell carcinoma cell proliferation and S-phase cell number in vitro. Moreover, urothelial carcinoma-associated 1 was found to be associated with enhancer of zeste homolog 2, which suppressed p21 expression through histone methylation (H3K27me3) on p21 promoter. We also showed that knockdown of urothelial carcinoma-associated 1 increased the p21 protein expression through regulating enhancer of zeste homolog 2. In addition, bioinformatics analysis and dual-luciferase reporter assays confirmed that miR-495 was a target of urothelial carcinoma-associated 1 in renal cell carcinoma, and urothelial carcinomaassociated 1 promoted cell proliferation by negatively regulating miR-495. These findings illuminated that urothelial carcinoma-associated 1 promoted renal cell carcinoma progression through enhancer of zeste homolog 2 and interacted with miR-495. Overall, overexpression of urothelial carcinoma-associated 1 functions as an oncogene in renal cell carcinoma that may offer a novel therapeutic target for renal cell carcinoma patients. KeywordsRenal cell carcinoma, urothelial carcinoma-associated 1, enhancer of zeste homolog 2, miR-495, tumor proliferation Long non-coding RNAs (lncRNAs), that are more than 200 bases in length, consist of exons and introns in structure, without ORFs, and are not highly conserved. Recent reports suggest that lncRNAs play an important role in regulation of diverse cellular processes such as cell growth and apoptosis and cancer metastasis. 5 Several lncRNAs have been reported to be participated in renal cancer, such as, Qiao et al. 6 found that a decrease in lncRNA growth arrest-specific 5 (GAS5) expression was associated with RCC genesis and progression and overexpression of GAS5 can inhibit the RCC progression. A recent study indicated that LncRNA metastasis-associated lung adenocarcinoma transcription 1 (MALAT1) could function as a competing endogenous RNA to regulate zinc finger e-box binding homeobox 2 (ZEB2) expression by sponging miR-200s in clear cell kidney carcinoma. 7 HOX transcript antisense RNA (HOTAIR) was overexpressed in RCC, and knockdown of HOTAIR led to the weakening of the recruitment and binding abilities of enhancer of zeste homolog 2 (EZH2) and H3K27me3 locus with lncRNA HOTAIR and inhibited cell prol...

show abstract

“…The expression of lncRNA C22orf32-1 was significantly upregulated in primary NPC tissues compared with the normal nasopharyngeal epithelial tissues, and therefore may act as an independent biomarker for early diagnosis and provide a novel therapeutic target for NPC (13,22,23). In the present study, the expression levels of lncRNA C22orf32-1 in 24 primary NPC tissues and 24 normal nasopharyngeal epithelial tissues were examined with one NPC and one normal nasopharyngeal epithelial cell line.…”

Section: Introductionmentioning

confidence: 99%

“…As the non-coding RNAs do not serve as the template for protein synthesis, they are considered superfluous in transcription. Multiple previous studies have demonstrated that lncRNAs take part in the development of numerous diseases, particularly via gene silencing, cell cycle regulating, chromatin remodeling and splicing regulating (13)(14)(15). The lncRNAs are categorized into oncogenes and tumor suppressor genes according to their different functions in variety of types of malignancy (16,17).…”

Section: Introductionmentioning

confidence: 99%

lncRNA C22orf32-1 contributes to the tumorigenesis of nasopharyngeal carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. The mechanism of nasopharyngeal carcinoma (NPC) remains unclear. The present study investigated the abnormal expression of long non-coding (lnc)RNAs in NPC tissues and one NPC cell line to identify the involvement of lncRNAs in the tumorigenesis of NPC. Using a quantitative reverse transcription polymerase chain reaction (RT-qPCR), the expression of lncRNA C22orf32-1 in NPC tissues and an NPC cell line was verified. The effects of lncRNA C22orf32-1 on NPC cells were investigated with a cell proliferation assay, cell scratch assay, Transwell assay and a cell apoptosis assay. The expression levels of lncRNA C22orf32-1 in NPC tissues and an NPC cell line were upregulated. lncRNA C22orf32-1 promoted the proliferation, migration and invasion of NPC cells, and reduced the apoptosis of NPC cells. The data demonstrated that lncRNA C22orf32-1 may facilitate the tumorigenesis of NPC, and may be used for the early diagnosis and treatment of NPC.

show abstract

Long noncoding RNAs: a potential novel class of cancer biomarkers

Cited by 231 publications

References 115 publications

Identification of differential expressed lncRNAs in human thyroid cancer by a genome‐wide analyses

Identification of differential expressed lncRNAs in human thyroid cancer by a genome‐wide analyses

LncRNA UCA1 promotes renal cell carcinoma proliferation through epigenetically repressing p21 expression and negatively regulating miR-495

lncRNA C22orf32-1 contributes to the tumorigenesis of nasopharyngeal carcinoma

Contact Info

Product

Resources

About